Legacy Private Trust Co. Sells 2,456 Shares of Danaher Corporation $DHR

Legacy Private Trust Co. lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 16.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 12,285 shares of the conglomerate’s stock after selling 2,456 shares during the quarter. Legacy Private Trust Co.’s holdings in Danaher were worth $2,722,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of DHR. EP Wealth Advisors LLC bought a new stake in Danaher in the second quarter worth about $3,807,000. Puzo Michael J bought a new stake in shares of Danaher in the 2nd quarter worth approximately $8,624,000. Madison Asset Management LLC bought a new stake in Danaher during the second quarter worth approximately $85,451,000. First Nebraska Trust Co acquired a new position in Danaher in the second quarter worth approximately $14,106,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Danaher in the second quarter valued at $11,800,000. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DHR. Stifel Nicolaus decreased their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Evercore reaffirmed an “outperform” rating and set a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Guggenheim boosted their price target on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Finally, Piper Sandler started coverage on shares of Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $234.09.

Danaher Stock Down 1.5%

Shares of NYSE:DHR traded down $3.22 during trading on Tuesday, reaching $217.99. 1,795,986 shares of the company traded hands, compared to its average volume of 4,452,666. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a market cap of $153.25 billion, a P/E ratio of 38.71, a price-to-earnings-growth ratio of 2.67 and a beta of 0.76. The firm has a fifty day simple moving average of $209.69 and a 200 day simple moving average of $193.88.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter last year, the firm earned $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. Analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.